NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 177 filers reported holding NEVRO CORP in Q1 2019. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $538,160 | -24.4% | 28,000 | 0.0% | 0.17% | -14.4% |
| Q2 2023 | $711,760 | -61.0% | 28,000 | +32.0% | 0.20% | -71.6% |
| Q3 2019 | $1,823,000 | +7.3% | 21,210 | -19.1% | 0.69% | +7.4% |
| Q2 2019 | $1,699,000 | -12.9% | 26,210 | -16.0% | 0.64% | -24.1% |
| Q1 2019 | $1,951,000 | +60.7% | 31,210 | 0.0% | 0.84% | +39.4% |
| Q4 2018 | $1,214,000 | – | 31,210 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |